BridgeMD
New treatment option for Nephrotic Syndrome With Edema (Diagnosis)
Official title SLIT ABS: Study on Patients With Autoimmune Podocytopathy
ClinicalTrials.gov ID: NCT07516964
What this study is testing
- What it's testing
- Nephrotic syndrome is a kidney condition that mainly affects children and is characterized by high levels of protein in the urine, low levels of protein in the blood, and swelling. While many children respond well to steroid treatment, a large proportion experience relapses or become dependent on therapy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 0 to 99
You may be able to join if
- Pediatric and adult patients with a diagnosis of podocytopathy
- Patients with nephrotic syndrome and/or histological diagnosis of minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), collapsing...
- Both newly diagnosed (incident) patients and patients already under follow-up at participating centers
- Availability of clinical data from medical records (including paper and/or electronic records, laboratory reports, and discharge summaries)
- Availability of biological samples (e.g., blood and/or renal biopsy), if collected as part of routine clinical care
You likely can't join if
- Refusal or inability of the patient, parents, or legal guardian to provide informed consent
- Lack of sufficient clinical data or unavailable biological samples required for the study
See the full eligibility criteria
- Pediatric and adult patients with a diagnosis of podocytopathy
- Patients with nephrotic syndrome and/or histological diagnosis of minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), collapsing glomerulopathy (CG), or diffuse mesangial sclerosis (DMS)
- Both newly diagnosed (incident) patients and patients already under follow-up at participating centers
- Availability of clinical data from medical records (including paper and/or electronic records, laboratory reports, and discharge summaries)
- Availability of biological samples (e.g., blood and/or renal biopsy), if collected as part of routine clinical care
- Signed informed consent by the patient or legal guardian (and assent when applicable)
- Refusal or inability of the patient, parents, or legal guardian to provide informed consent
- Lack of sufficient clinical data or unavailable biological samples required for the study
The study team makes the final eligibility decision.
Where it's taking place
- Rochester, Minnesota, United States
- München, Germany
- Bagno a Ripoli, Firenze, Italy
- Florence, FIRENZE, Italy
- Bologna, Italy
- Florence, Italy
- Genova, Italy
- Parma, Italy
- Pisa, Italy
- Prato, Italy
- Reggio Emilia, Italy
- Mexico City, Mexico
- Barcelona, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0 years to 99 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rochester, Minnesota, United States; München, Germany; Bagno a Ripoli, Firenze, Italy; Florence, FIRENZE, Italy; Bologna, Italy; Florence, Italy and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.